Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 12, 2013Blood

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRoland B. WalterCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaSBSarah BuckleyBG Medicine (United States)JPJohn M. PagelEppendorf (Germany)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Walter et al. (2013) studied this question.

synapsesocial.com/papers/69fcdf0ff9b1bbfa2c26fe7chttps://doi.org/10.1182/blood-2013-06-506725
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials2010 · 1,972 citations
  2. 2The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes2009 · 4,458 citations
  3. 3High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia2011 · 173 citations
  4. 4Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia2012 · 187 citations
  5. 5Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia2008 · 174 citations